BCAT1 and B-cell chronic lymphocytic leukemia: The expression of BCAT1 was also evaluated in CLL patients and ibrutinib‐resistant cells as BCAT1 is known to play roles in metabolic reprogramming, disease progression and drug resistance [37, 38, 44].